No data to show
XHKG
2252
Market cap2.39bUSD
May 09, Last price
18.62HKD
1D
0.00%
1Q
21.54%
Name
MicroPort MedBot Shanghai Co Ltd
Chart & Performance
P/E
—
P/S
67.31
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.29%
Rev. gr., 5y
%
Revenues
257m
+145.95%
Net income
-642m
L-36.53%
CFO
0k
P
Profile
Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; Honghu, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. The company also provides spine surgical robots; trans-bronchial surgical robots for trans-bronchial diagnosis and treatment; TAVR surgical robots for heart valve replacement surgery; and automated needle targeting robotics systems for percutaneous lung biopsy and percutaneous nephrolithotomy. Shanghai Microport Medbot (Group) Co., Ltd. was founded in 2014 and is based in Shanghai, China. Shanghai Microport Medbot (Group) Co., Ltd. operates as a subsidiary of MicroPort Scientific Corporation.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 257,249 145.95% | 104,592 384.15% | 21,603 904.79% | |||
Cost of revenue | 742,970 | 1,023,862 | 1,125,357 | |||
Unusual Expense (Income) | ||||||
NOPBT | (485,721) | (919,270) | (1,103,754) | |||
NOPBT Margin | ||||||
Operating Taxes | 20,506 | |||||
Tax Rate | ||||||
NOPAT | (485,721) | (919,270) | (1,124,260) | |||
Net income | (642,406) -36.53% | (1,012,174) -13.25% | (1,166,790) 115.00% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | 279,734 | 423,236 | 58,218 | |||
Long-term debt | 468,385 | 257,575 | 348,582 | |||
Deferred revenue | 34,804 | |||||
Other long-term liabilities | 106,311 | 103,687 | 397 | |||
Net debt | 56,948 | (42,098) | (625,918) | |||
| Cash flow | ||||||
Cash from operating activities | (567,843) | (898,475) | ||||
CAPEX | (64,985) | (194,815) | ||||
Cash from investing activities | (58,385) | (267,825) | ||||
Cash from financing activities | 385,676 | (27,946) | ||||
FCF | (412,371) | (735,244) | (1,338,600) | |||
| Balance | ||||||
Cash | 612,230 | 507,711 | 747,962 | |||
Long term investments | 78,941 | 215,198 | 284,756 | |||
Excess cash | 678,309 | 717,679 | 1,031,638 | |||
Stockholders' equity | 257,678 | (640,514) | (598,241) | |||
Invested Capital | 797,638 | 1,806,381 | 2,261,270 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 966,917 | 958,594 | 958,594 | |||
Price | 9.51 -54.06% | 20.70 -34.91% | 31.80 -46.42% | |||
Market cap | 9,195,381 -53.66% | 19,842,896 -34.91% | 30,483,288 -44.16% | |||
EV | 9,231,805 | 20,646,923 | 29,847,590 | |||
EBITDA | (485,721) | (807,511) | (1,003,048) | |||
EV/EBITDA | ||||||
Interest | 18,408 | 11,126 | ||||
Interest/NOPBT | ||||||